Claire Harrison, MD, DM, FRCP, FRCPath, from Guys and St Thomas’ NHS Foundation Trust, London, UK provides a general overview on emergent therapies in myeloproliferative malignancies. She talks about understanding molecular features of the disease in more depth in order to better target drugs. Prof Harrison provides a great outline of new data on therapies being generated around the world. She also provides insight into how one might go about devising treatment strategies that are tailored to the individual patient for e.g. molecular disease status. Lastly, she discusses emergent therapies for the rarer myeloproliferative malignancies which have shown promising results.